Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Turner Syndrome Society Of The United States Announces Ambitious Goal To Crush Ignorance Of Turner Syndrome (TS)
The Turner Syndrome Society of the United States (TSSUS) recently concluded its 22nd Annual Conference in Portland, Oregon. The conference drew more than 350 individuals, families, researchers and health care professionals to network and learn about the latest research breakthroughs benefiting women and girls with TS.
generic viagra online
Columnist Discusses Recent Findings On Teenage Condom Use, HIV Prevention
"In the past few months, we"ve experienced near hysteria over swine flu and almost constant media attention to scares about tainted food," syndicated columnist Marie Cocco writes in the Oregonian, adding, "These are genuine health hazards - but they aren"t necessarily deadly, nor do they affect nearly as many people in the United States and around the world as does AIDS." Cocco discusses a recent finding by researchers from Columbia University and the Alan Guttmacher Institute that links a drop in condom use among teenagers "in part to waning public concern about transmission of HIV." She writes, "The clear increase in the proportion of teenagers using condoms came during years when public health and media messages about the dangers of HIV were at a height." Cocco continues, "You can argue, based on hard data, that when it comes to teenagers and sex, good policy and genuine leadership get better results than moralizing or ignoring signals that an upsurge in HIV infections may emerge" (Cocco, 7/2).
News of the day
Data From Enzo Therapeutics' Phase II Study Of Crohn's Disease Presented At Prestigious Gastroenterology Conference
Enzo Biochem, Inc. (NYSE: ENZ), a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services, announced that data from a Phase II clinical trial was presented today at Digestive Disease Week, the largest international gathering of academic researchers and practicing physicians in gastrointestinal medicine, held this year in Chicago. The data indicate that Alequel™, the Company"s investigational individualized oral immune regulation preparation, may be effective for the treatment of moderate-to-severe Crohn"s disease.
Public Health

Novel Peripheral IV Catheter: Telesso Technologies Wins Popular Science Invention Award

Telesso Technologies Limited (ASX: TEO), a global healthcare company, has announced the FDA-approved guide wire-assisted peripheral IV catheter it is developing with Vascular Pathways, Inc., has been honored with the Popular Science Invention Award. "Telesso is pleased to receive another exciting external validation of this innovative device that may revolutionize peripheral IV placement," said Telesso"s CEO Nelson K. Stacks. "Attempts to start an IV frequently fail, which is frustrating for clinicians, painful for patients and costly to the health care system. The new guide-wire assisted peripheral IV catheter uses a practical design to improve the ability for clinicians to get it right the first time, creating efficiency, enhancing safety, reducing costs, and avoiding the need for re-sticks." A post-market trial is currently comparing patients treated with Telesso"s catheter to the industry"s gold standard device for peripheral IV placement. Data review is expected in Q2-Q3 2009. About the Guide Wire-Assisted Peripheral IV Cathete A peripheral vein is the most common site for insertion of a catheter for short-term diagnostic or therapeutic use. The catheter is placed into the peripheral vein in the arm and is typically passed up inside the vein to a length of 2-3 inches. Telesso"s uniquely-designed guide wire-assisted peripheral IV catheter device uses a first-in-class retractable nitinol guide wire system that is believed to enable easier IV access, reduce common safety risks, significantly lessen patient pain and discomfort, and provide cost savings to facilities by lowering administrative costs associated with failed IV starts. Telesso believes this catheter device is the first clinically meaningful advancement in peripheral IV access since automatic needle retraction catheters and addresses significant unmet needs in peripheral intravenous access. About the Telesso-VPI Agreement Telesso Technologies Limited announced in December 2008 that it entered into a strategic agreement with Vascular Pathways, Inc. (VPI), a private company based in California, to co-develop VPI"s guide wire-assisted device with the funding of the clinical trial and to potentially acquire VPI. Jeff Riley Cytori Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009